Special Issue

B Cell-Mediated Immunity to Viruses

Message from the Guest Editor

B cell-mediated humoral immune response, also known as antibody-mediated response, plays a critical role in host defense against invading pathogens and is a key determinant for the development of most effective vaccines. Studying broadly neutralizing antibodies and understanding the rules for eliciting broadly neutralizing B cell responses will help antibody-based therapies and vaccine development. In addition, antibody functions are varied, and not all pathogen-specific antibodies benefit the host. Hence, the scope of this topic is related to B cell development, function, epitopes and application in the face of infectious pathogens.

Guest Editor

Prof. Dr. Haiyan Zhao

State Key Laboratory of Virology and Biosafety, College of Life Sciences, Wuhan University, Wuhan, China

Deadline for manuscript submissions

closed (31 March 2025)

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/189650

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/viruses

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/viruses

About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed
HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).